Key facts
- Conexeu Sciences’s last known valuation is $35.3M (Oct 2025).
- It has raised $12.4M across 4 recorded rounds; the latest was Seed Round ($1.8M) in Mar 2026.
- Notable investors include The University of British Columbia.
- Conexeu Sciences has filed 9 Form Ds with the SEC since 2025, most recently Jun 2026 ($86K sold to 2 investors).
- Status: In IPO Registration.
Investors
1- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Conexeu Sciences
Funding rounds
4 roundsAbout Conexeu Sciences
Developer of a human collagen-based liquid extracellular matrix designed to promote tissue formation and accelerate healing. The company offers a thermosensitive scaffold that transitions from liquid to gel at body temperature, promoting cell migration, differentiation, and seamless integration into host tissue, enabling regenerative medicine applications and improving healing outcomes while reducing inflammation and scarring.
- Sector
- Healthcare
- HQ
- Reno, NV, United States
- Founded
- 2022
- Employees
- 10
- Website
- conexeu.com/
- Ownership
- In IPO Registration
Conexeu Sciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Conexeu Sciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Conexeu Sciences in its N-PORT filings yet. We sweep new filings monthly.